Current models of prostate cancer classification are poor at distinguishing between tumors
that have similar histopathological features but vary in clinical course and outcome. Here …

Prostate cancer, a leading cause of cancer death, displays a broad range of clinical
behavior from relatively indolent to aggressive metastatic disease. To explore potential …

One of the major problems in management of prostate cancer is the lack of reliable genetic
markers predicting the clinical course of the disease. We analyzed expression profiles of …

Prostate cancer is the second most prevalent malignancy in men. Biomarkers for outcome
prediction are urgently needed, so that high‐risk patients could be monitored more closely …

Prostate cancer remains the second leading cause of cancer death in American men and
there is an unmet need for biomarkers to identify patients with aggressive disease. In an …

Clinical outcomes in prostate cancer are heterogeneous, and given the high prevalence of
the disease, there is a pressing need to identify clinically useful markers of prognosis. Many …

BACKGROUND Molecular characterization of prostate cancer (PCa) has revealed distinct
subclasses based on underlying genomic alterations occurring early in the natural history of …

Background Prostate cancer is characterized by heterogeneity in the clinical course that
often does not correlate with morphologic features of the tumor. Metastasis reflects the most …

BACKGROUND The derivation of molecular signatures indicative of disease status and
predictive of subsequent behavior could facilitate the optimal choice of treatment for prostate …

Recently, many therapeutic agents for prostate cancer have been approved that target the
androgen receptor and/or the prostate tumor microenvironment. Each of these therapies has …